Voluntary recall of losartan expanded

After finding trace amounts of an “unexpected impurity,” Torrent Pharmaceuticals Limited has expanded its voluntary recall of losartan potassium tablets. The impurity is N-Methylnitrosobutyric acid.

The expanded recall includes an additional three lots of losartan potassium tablets USP and two lots of losartan potassium/ydrochlorothiazide tablets. Only lots of losartan NMBA above the acceptable daily intake levels released by the FDA are being recalled.

Bayer recall

Last week Bayer discovered that vials of one of their top-selling hemophilia drugs had been filled with the wrong medicine. The vials are labeled as containing Kegenate FS but they actually are filled with VIII hemophilia A treatment Jivi. All but 990 vials were caught before they made it into the marketplace.

AbbVie to buy Allergan

AbbVie, a biopharmaceutical company, said it plans to buy Botox maker Allergan for about $63 billion, to help reduce its reliance on blockbuster arthritis treatment Humira.

Humira, the world's best-selling drug, already has cheaper versions available in Europe and has its US patents expiring in 2023.

Who were the 20 highest paid CEOs in 2018?

FiercePharma has calculated the top CEO pay packages in biopharma in 2018. The salaries range from nearly $60 million down to $16 million. Amongst the data are some notable trends. First, no women made the list. Emma Walmsley, Big Pharma’s only women CEO had a pay package of $7.75 million, which if doubled still would not make the top 20. Other Big Pharma CEOs not on the list are Novartis, Roche and Sanofi.